Short, plain-language guides on GLP-1 therapy and metabolic health, written and reviewed by ZIVOLABS doctors. No clickbait. No miracle promises.
Browse the full article libraryA common switch for better blood-sugar and weight results; your doctor will re-titrate from a low semaglutide dose.
Both are weekly Lilly injections, so the switch is familiar, but Mounjaro is substantially stronger for weight loss.
Switching from daily liraglutide to weekly semaglutide usually means fewer injections and greater weight loss — a popular move.
Switching to the tablet suits needle-averse patients, but expect milder results and remember the strict empty-stomach routine.
Moving from the oral tablet to the weekly injection usually means more weight loss and no more fasted-dosing ritual — a common upgrade.
Often a cost or supply decision. Since both are semaglutide, your dose carries over directly with no re-titration needed.
Same molecule, so the switch is smooth — Wegovy simply allows a higher weight-loss dose (up to 2.4 mg) under its weight-management label.
People switch this way usually for cost or availability. Expect a small step back in average weight loss, but semaglutide remains highly effective.
Switching from semaglutide to tirzepatide can break a weight-loss plateau and often increases total weight loss, thanks to Mounjaro's dual hormone action.
Two very different paths. GLP-1 delivers ~15–20% weight loss medically; bariatric surgery delivers ~25–35% but is a permanent operation.
Two very different paths. GLP-1 delivers ~15–20% weight loss medically; bariatric surgery delivers ~25–35% but is a permanent operation.
Two very different paths. GLP-1 delivers ~15–20% weight loss medically; bariatric surgery delivers ~25–35% but is a permanent operation.
